- Home
- BHAT vs BTAI Comparison
BHAT vs BTAI Comparison
Compare BHAT & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHAT
- BTAI
- Stock Information
- Founded
- BHAT 2010
- BTAI 2017
- Country
- BHAT China
- BTAI United States
- Employees
- BHAT N/A
- BTAI N/A
- Industry
- BHAT Recreational Games/Products/Toys
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- BHAT Consumer Discretionary
- BTAI Health Care
- Exchange
- BHAT Nasdaq
- BTAI Nasdaq
- Market Cap
- BHAT 10.3M
- BTAI 8.3M
- IPO Year
- BHAT 2019
- BTAI 2018
- Fundamental
- Price
- BHAT $1.74
- BTAI $1.79
- Analyst Decision
- BHAT
- BTAI Buy
- Analyst Count
- BHAT 0
- BTAI 5
- Target Price
- BHAT N/A
- BTAI $34.60
- AVG Volume (30 Days)
- BHAT 785.0K
- BTAI 291.8K
- Earning Date
- BHAT 04-30-2025
- BTAI 08-05-2025
- Dividend Yield
- BHAT N/A
- BTAI N/A
- EPS Growth
- BHAT N/A
- BTAI N/A
- EPS
- BHAT N/A
- BTAI N/A
- Revenue
- BHAT $18,724,190.00
- BTAI $1,852,000.00
- Revenue This Year
- BHAT N/A
- BTAI $5.03
- Revenue Next Year
- BHAT N/A
- BTAI $291.01
- P/E Ratio
- BHAT N/A
- BTAI N/A
- Revenue Growth
- BHAT N/A
- BTAI 5.47
- 52 Week Low
- BHAT $1.62
- BTAI $1.17
- 52 Week High
- BHAT $145.00
- BTAI $21.92
- Technical
- Relative Strength Index (RSI)
- BHAT 41.28
- BTAI 62.90
- Support Level
- BHAT $1.75
- BTAI $1.59
- Resistance Level
- BHAT $2.12
- BTAI $2.22
- Average True Range (ATR)
- BHAT 0.12
- BTAI 0.21
- MACD
- BHAT -0.01
- BTAI 0.04
- Stochastic Oscillator
- BHAT 4.90
- BTAI 75.00
About BHAT Blue Hat Interactive Entertainment Technology
Blue Hat Interactive Entertainment Technology is a producer, developer, and operator of augmented reality (AR) interactive entertainment games and toys in China, including interactive educational materials, mobile games, and toys with mobile game features. The company's products include AR Racer, AR Crazy Bug, AR 3D Magic Box, AR Dinosaur, Talking Tom and Friends Bouncing Bubble, and Immersive Education Classes. The company reports in the following segments: Interactive toys - animation series, Interactive toys - game series, and Mobile games, Information services, and Communication services, out of which the majority of the revenue is generated from the game series. The majority of its revenues are generated in China.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.